the treatment of their LBP with an already in-place, thorough care plan of their depression. Many, in fact, may be presenting to their pain physician without even knowing they are in fact depressed, have not brought this up in conversation with their primary care physician, or may not even have a primary provider to begin with.
The take-home point therefore must be, although it may not be within our expertise to accurately diagnose or treat depression in our patients, simply documenting their potential depression or taking note that they are taking prescribed antidepression medications is not enough. A portion of our visit time needs to be allocated to addressing their depression and creating opportunities for the majority of patients who do not already have a tailored care plan in place to address their depression. Given that they are now in front of us, providers need to take advantage of this to address their concurrent depression because they may not do so on their own or may not have the means to find another provider to help them with this. Whether this includes a referral to a psychologist, pain psychologist, psychiatrist, or primary care provider to establish care with or a counselor or therapist for monthly or weekly sessions, or even a personal call to their established psychiatry care providing provider to effectively close the loop or foster interdisciplinary care, some further propagation of their depression care needs to be initiated and put in place at this visit.
If their depression is not addressed and only their LBP is, we as providers may unfortunately be finding that our treatments and care plans may not be as efficacious and are only serving as a Band-Aid or cover for their concurrent depression, which may have been a proponent in their care seeking for their activity-limiting LBP to begin with.
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We report a patient who was exposed to Risperidone, Trihexyphenidyl, and Paroxetine during first trimester of pregnancy.
A 25-year-old female patient with diagnosis of paranoid schizophrenia since 2009 was on treatment from our department since 2012, and she was showing significant improvement on maintenance dose of fixed-dose combination of Risperidone 3mg plus Trihexyphenidyl 2 mg one tablet at night. The patient got married in 2015, and the patient and her family members were explained about need to take contraceptive measures. Paroxetine 25 mg was added in December 2015 for obsessive-compulsive symptoms, and on next follow-up in February 2016, as the patient had no obsessivecompulsive symptoms, paroxetine was reduced to 12.5 mg. On next follow-up after 1 month (March 2016), the patient had no active symptoms and she reported about her pregnancy (she had the last menstrual period in January). Patient and her sister were told about probable teratogenic effects of medicines and they opted to continue medicine. Paroxetine was stopped and fixed-dose combination of Risperidone 3 mg plus Trihexyphenidyl 2 mg was continued at same dose. She was monitored regularly with ultrasonography. The patient delivered a male baby in November 2016. Infant was examined by a pediatrician when he was 3 months old, and no obvious congenital abnormality or delay in milestones was detected. Hence, she received Risperidone and Trihexyphenidyl throughout the pregnancy and paroxetine for approximately 2 months (first trimester)
DISCUSSION
Risperidone exposure is found to cause fetal malfor mations including Ivemark syndrome, Pierre-Robin syndrome, cardiomyopathy, cleft lip and palate, ear abnormalities, gastroschisis, gestational diabetes, and Turners' syndrome. [2] A systematic review of pregnancy exposure to various antipsychotics and risk of congenital malformations reported 22 malformations in 432 pregnancies exposed to Risperidone, resulting in malformation rate of 5.1%. [3] Two studies have shown a doubled or tripled risk of right ventricular outflow tract obstruction associated with paroxetine use. [4, 5] There is a case report of two uncomplicated pregnancies in one woman with sporadic, primary generalized dystonia treated with high dosage Trihexyphenidyl. [6] Until now, no case report has reported the successful use of a combination of Risperidone, Trihexyphenidyl, and Paroxetine during first trimester of pregnancy.
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